Patient Guide: A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 19 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06522737
Status: 🟢 Enrolling Now
Condition: Lymphoma
Phase: PHASE3

Where You Can Participate

This study is available at 19 locations across the country.

Top locations include:
  • • Prague 2,
  • • Rouen, Normandy
  • • Caen,
  • • And 16 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype - Join Clinical Trial NCTNCT06522737

How to Join This Clinical Trial - NCTNCT06522737

Learn how to participate in this PHASE3 trial studying an investigational therapy for Lymphoma. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Lymphoma. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Lymphoma
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06522737 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 19 locations. Find a study site near you:

Clinical Research Site

Prague 2, 128 08 - Czechia

Status: NOT_YET_RECRUITING

Clinical Research Site

Rouen, Normandy 76038 Cedex 1 - France

Status: NOT_YET_RECRUITING

Clinical Research Site

Caen, 14033 - France

Status: NOT_YET_RECRUITING

Clinical Research Site

Clermont-Ferrand, 63000 - France

Status: NOT_YET_RECRUITING

Clinical Research Site

Montpellier, 34295 - France

Status: RECRUITING

Clinical Research Site

Nantes, 44093 - France

Status: NOT_YET_RECRUITING

Clinical Research Site

Paris, 75019 - France

Status: NOT_YET_RECRUITING

Clinical Research Site

Pessac, 33604 - France

Status: NOT_YET_RECRUITING

Clinical Research Site

Alessandria, 15121 - Italy

Status: NOT_YET_RECRUITING

Clinical Research Site

Bergamo, 24127 - Italy

Status: NOT_YET_RECRUITING

And 9 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Lymphoma:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships